Details About Generic Salt ::  Aminocap

Main Medicine Class:: Hemostatic   

(uh-mee-no-kuh-PRO-ik acid)

Amicar

Injection: 250 mg/mL, Tablets: 500 mg, Syrup: 250 mg/mL

Class: Hemostatic

 

Drugs Class ::

 Actions Inhibits fibrinolysis to stop bleeding.

Indications for Drugs ::

 Indications Treatment of excessive bleeding from systemic hyperfibrinolysis and urinary fibrinolysis.

Prevention of recurrence of subarachnoid hemorrhage; management of amegakaryocytic thrombocytopenia; abortion or prevention of attacks of hereditary angioneurotic edema.

Drug Dose ::

 Route/Dosage

ADULTS: IV/PO 4 to 5 g in first hour; then 1 to 1.25 g/hr for 8 hr or until bleeding is controlled. Dosage > 30 g/24 hr is not recommended.

Contraindication ::

 Contraindications Active intravascular clotting; DIC; administration to newborns.

Drug Precautions ::

 Precautions

Pregnancy: Category C.

Lactation: Undetermined.

Upper urinary tract bleeding: Not used in treatment of hematuria of upper UT origin unless possible benefits outweigh risks.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Hypotension. CNS: Dizziness; headache; delirium; auditory, visual and kinesthetic hallucinations; weakness; convulsions.DERMATOLOGIC: Skin rash. EENT: Conjunctival suffusion; tinnitus; nasal congestion. GI: Nausea; diarrhea; abdominal cramps. GU: Reversible acute renal failure; intrarenal obstruction. HEMATOLOGIC: Thrombophlebitis. OTHER: Malaise; myopathy (characterized by weakness, fatigue, elevated levels of serum enzymes such as creatinine phosphokinase); rhabdomyolysis.

Drug Mode of Action ::  

 Actions Inhibits fibrinolysis to stop bleeding.

Drug Interactions ::

 Interactions

Oral Contraceptives or Estrogens: May lead to increase in clotting factors, producing state of hypercoagulation.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Determine baseline BP and pulse before starting IV infusion.
• Assess patient’s respiratory and neurologic status.
• Note presence of menstrual bleeding.
• Monitor serum potassium levels, clotting factors, and platelet counts.
• Monitor vital signs, especially BP and pulse, and respiratory and neurologic status throughout therapy.
• Monitor I&O. Note any increase or decrease in urinary output.
• Observe for signs of internal bleeding (eg, petechiae, gingival oozing, hematuria, epistaxis, ecchymosis).
• Have vitamin K or protamine sulfate available for emergency use.

Drug Storage/Management ::

 Administration/Storage

IV Infusion

• Dilute as 1 g/50 mL diluent. Compatible diluents include Sterile Water for Injection, normal saline, D5W, and Ringer’s solution.
• Use infusion pump for IV administration. Closely monitor rate of infusion because this drug is not intended for rapid IV injection or in undiluted form.
• Infuse dose over 30 min to 1 hr.

Oral Administration

• Give with full glass of water.
• Encourage fluid intake between doses.
• Store in tightly closed container at room temperature.

Drug Notes ::

 Patient/Family Education

• Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
• Advise patient to use soft toothbrush or sponge for dental care.
• Instruct patient to report the following symptoms to health care provider: Gingival bleeding, epistaxis, hematuria, skin changes (eg, ecchymosis, petechiae), difficulty in urination, reddish-brown urine, chest or leg pain, or breathing difficulty.

–>

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.